Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan.
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e866-e874. doi: 10.1210/clinem/dgaa812.
Current clinical guidelines recommend confirmation of a positive result in at least one confirmatory test in the diagnosis of primary aldosteronism (PA). Clinical implication of multiple confirmatory tests has not been established, especially when patients show discordant results.
The aim of the present study was to explore the role of 2 confirmatory tests in subtype diagnosis of PA.
A retrospective cross-sectional study was conducted at two referral centers.
We identified 360 hypertensive patients who underwent both a captopril challenge test (CCT) and a saline infusion test (SIT) and exhibited at least one positive result. Among them, we studied 193 patients with PA whose data were available for subtype diagnosis based on adrenal vein sampling (AVS).
The prevalence of bilateral subtype on AVS according to the results of the confirmatory tests was measured.
Of patients studied, 127 were positive for both CCT and SIT (double-positive), whereas 66 were positive for either CCT or SIT (single-positive) (n = 34 and n = 32, respectively). Altogether, 135 were diagnosed with bilateral subtype on AVS. The single-positive patients had milder clinical features of PA than the double-positive patients. The prevalence of bilateral subtype on AVS was significantly higher in the single-positive patients than in the double-positive patients. (63/66 [95.5%] vs 72/127 [56.7%], P < .01). Several clinical parameters were different between CCT single-positive and SIT single-positive patients.
Patients with discordant results between CCT and SIT have a high probability of bilateral subtype of PA on AVS.
目前的临床指南建议在原发性醛固酮增多症(PA)的诊断中,至少对一项确证试验的阳性结果进行确证。尚未确定多项确证试验的临床意义,特别是当患者的结果不一致时。
本研究旨在探讨 2 项确证试验在 PA 亚型诊断中的作用。
这是一项在两个转诊中心进行的回顾性横断面研究。
我们确定了 360 名接受卡托普利挑战试验(CCT)和盐水输注试验(SIT)且至少有一项阳性结果的高血压患者。其中,我们研究了 193 名根据肾上腺静脉采样(AVS)可进行亚型诊断的 PA 患者。
根据确证试验结果测量 AVS 双侧亚型的患病率。
在所研究的患者中,127 例 CCT 和 SIT 均为阳性(双阳性),66 例 CCT 或 SIT 阳性(单阳性)(n=34 和 n=32)。共有 135 例患者在 AVS 上诊断为双侧亚型。单阳性患者的 PA 临床特征比双阳性患者更轻。单阳性患者的 AVS 双侧亚型患病率显著高于双阳性患者(63/66[95.5%]比 72/127[56.7%],P<0.01)。CCT 单阳性和 SIT 单阳性患者的几个临床参数不同。
CCT 和 SIT 结果不一致的患者在 AVS 上双侧亚型 PA 的可能性较高。